- Mechanism of action
- Binds the oxytocin receptor (OTR, Gq-coupled) in uterus, mammary gland and CNS; modulates uterine contraction, milk ejection and social signal processing.
- Benefits & use
- Labour induction and augmentation, control of postpartum haemorrhage; in studies, appetite regulation and modulation of social cognition and bonding.
- Study status
- Pitocin FDA-approved for decades; Plessow et al., NEJM Evid 2024 (PMID 38815173) RCT in obesity; Finger et al., FOXY Phase 2 in frontotemporal dementia (PMID 30261917); NCT03197662 in Prader-Willi syndrome.
- Dosing note
- No dosage advice here. Pitocin (FDA label): intravenous only, in hospital under continuous monitoring; intranasal oxytocin is investigational, no approved product.
Use in the injection calculator
Oxytocin is an endogenous peptide hormone from the nonapeptide family, produced in the hypothalamus (paraventricular and supraoptic nuclei) and released via the posterior pituitary. Through the oxytocin receptor (OTR) it drives uterine contraction, milk ejection and social cognition. As synthetic Pitocin it has been FDA-approved for decades; intranasal formulations are under active research.
What is Oxytocin and how does it work?
The oxytocin molecule is a nine-amino-acid peptide with a disulfide bridge between Cys1 and Cys6. Receptor binding activates a Gq-coupled cascade and intracellular calcium release. Key sites of action are:
- Uterus: increased frequency and strength of contractions,
- Mammary gland: triggering of the milk-ejection reflex,
- CNS: modulation of reward, anxiety and social cognition (amygdala, nucleus accumbens, prefrontal cortex).
What is Oxytocin approved for?
The approved clinical form is Pitocin (FDA label: 10 IU per mL injection solution). Approved indications include:
- induction and augmentation of labour,
- control of postpartum haemorrhage (placental delivery, uterine atony),
- historically: support of milk ejection (nasal Syntocinon - withdrawn from the US market in 1995).
Administration is intravenous only, in hospital, under continuous monitoring - the FDA label explicitly warns against uterine overstimulation and fetal distress.
Which studies are ongoing?
Intranasal oxytocin is being tested in randomised trials for numerous off-label indications. A double-blind RCT in adults with obesity (Plessow et al., NEJM Evid 2024, PMID 38815173) examined effects on caloric intake and body weight. The Phase 2 FOXY trial (Finger et al., PMID 30261917) is testing intranasal oxytocin in frontotemporal dementia; a study in Prader-Willi syndrome (NCT03197662) has completed enrolment.
How is Oxytocin used and stored?
Pitocin ships as a ready-to-use injection solution - you do not reconstitute it yourself. If you are working with research material, follow the peptide storage guide: powder and mixed solution (lyophilisate cool, dry, dark; reconstituted solution at 2-8 °C). For dose work with other peptides, see the injection calculator and the calculating a peptide dose guide.
Related peptides
Sources
- Pitocin - FDA Label (NDA 018261)
- Plessow F et al. Intranasal Oxytocin for Obesity. NEJM Evid 2024 (PMID 38815173)
- Finger E et al. FOXY - Phase 2 intranasal oxytocin in frontotemporal dementia. Alzheimers Res Ther 2018 (PMID 30261917)
- ClinicalTrials.gov NCT03197662 - Intranasal Oxytocin in Prader-Willi Syndrome